Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Antihypertensive Drugs: Thiazide-Class Diuretics

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reprint of: The impact of alpha-1-adrenergic receptor antagonists on the progression of Parkinson disease.

Journal of the American Pharmacists Association : JAPhA·2024

Same author

Glucagon-like peptide receptor agonists and risk for depression.

Primary care diabetes·2024

Same author

The impact of alpha-1-adrenergic receptor antagonists on the progression of Parkinson disease.

Journal of the American Pharmacists Association : JAPhA·2023

Same author

Enoxaparin Use and Adverse Events in Outpatients With a Continuous Flow Left Ventricular Assist Device at a Single Institution.

Journal of pharmacy practice·2021

Same author

Lack of Association between 5α-Reductase Inhibitors and Depression.

The Journal of urology·2020

Same author

Comparative Effectiveness of Anticholinergic Agents for Lower Urinary Tract Symptoms.

Journal of managed care & specialty pharmacy·2018

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

Silodosin for benign prostatic hyperplasia.

Matthew A Cantrell¹, Heather R Bream-Rouwenhorst, Phyllis Hemerson

¹College of Pharmacy, University of Iowa; Clinical Pharmacy Specialist, Veterans Affairs Medical Center, Iowa City, IA, USA. matthew.cantrell@va.gov

The Annals of Pharmacotherapy

|January 15, 2010

Summary

Silodosin effectively reduces benign prostatic hyperplasia (BPH) symptoms and improves urinary flow rates. While generally safe, long-term studies are needed to confirm its cardiovascular safety and clinical outcomes, especially in specific patient groups.

Related Experiment Videos

Last Updated: Jun 17, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

Area of Science:

Pharmacology and Therapeutics
Urology

Background:

Benign prostatic hyperplasia (BPH) is a common condition in aging men, causing lower urinary tract symptoms.
Alpha(1A)-adrenergic receptor (AR) antagonists are a primary treatment for BPH.

Purpose of the Study:

To review the pharmacology, pharmacokinetics, clinical trials, and safety of silodosin, a selective alpha(1A)-AR antagonist for BPH.

Main Methods:

A literature search of MEDLINE and International Pharmaceutical Abstracts was conducted for English-language articles on silodosin (KMD-3213).
Available English and non-English article abstracts were reviewed.

Main Results:

Silodosin demonstrated rapid reduction of BPH symptoms and improved urinary flow rates, comparable to other alpha(1)-AR antagonists.
The most common adverse effect was ejaculatory disturbances; cardiovascular side effects like orthostatic hypotension were minimal in preliminary data.
Dosing adjustments are recommended for moderate renal dysfunction, and use is contraindicated in severe renal/hepatic impairment or with strong CYP3A4 inhibitors.

Conclusions:

Silodosin, approved in 2008, shows promise for BPH treatment.
Long-term outcome data and pharmacoeconomic analyses are pending.
Silodosin may serve as an alternative alpha(1A)-AR antagonist for BPH management.